Second quarter operating expenses were USD 4,594 thousand against USD 7,031 thousand a year earlier, including a provision forCreditlosses of USD 2,059 thousand and general and administrative expense of USD 1,723 thousand. Management gives no formal financial guidance and framed its outlook as priorities …
The operating loss was USD 11.1 million in the second quarter and USD 23.7 million for six months. Research and development expense was USD 3.9 million, down 73% year over year, and USD 11.9 million for six months, down 45%. Management expects significant losses …
The Rationale: Last Reported Quarter and Management Outlook for Vivos Therapeutics, Inc. (NASDAQ:VVOS)
In the second quarter, gross margin reached 56.4% against 42.6% a year earlier, and net income was USD 288,000 compared with a net loss of USD 6.1 million. The six-month net loss was USD 6.3 million, and Adjusted EBITDA was a loss of USD …
Operating expenses fell to USD 6.0 million from USD 31.8 million, mainly because stock-based compensation dropped by USD 24.1 million, which the company ties to a one-time share issuance in the second quarter of 2025. The loss from operations narrowed to USD 4.4 million …
Second quarter non-GAAP net loss was USD 1.3 million, or USD 0.21 per share, against USD 0.9 million, or USD 0.37 per share, a year earlier. Adjusted EBITDA was a loss of USD 479,000 versus USD 299,000, though the prior-year quarter included a benefit …
In its preliminary fiscal 2026 results, announced on October 1, 2026, the company reported revenue of about USD 5.17 million and a net loss of USD 11.1 million. Acting Chief Executive Officer Sam Teo called fiscal 2026 a pivotal period, pointing to steadyQuarterly Revenue …
The second quarter net loss of USD 2.87 million included USD 756,554 of intangible amortization, USD 273,710 ofTransaction Costsand USD 144,495 tied to recalling all SilverSeal inventory from Amazon. Management said rollout moved more slowly than planned. Sequence deployed tissue processing specialists to the …
The Rationale: Last Reported Quarter and Management Outlook for Edible Garden AG Incorporated (NASDAQ:EDBL)
Second quarterGross Profitwas USD 732,003 versus USD 1,938,277, and operating expenses fell 31% to USD 1.70 million. The operating loss was USD 965,508 and Adjusted EBITDA was a loss of USD 776,256. Management attributed the revenue drop to slower new sales at Eastern Standard …